OssiMend Bioactive Moldable in Posterolateral Instrumented Lumbar Fusion
Collagen Matrix
Summary
The primary objective of this study is to measure the success rate of lumbar fusion in subjects at 12 months when instrumented lumbar arthrodesis is performed using OssiMend Bioactive Moldable as the bone grafting material
Description
The primary objective of this study is to measure the success rate of lumbar fusion in subjects at 12 months when instrumented lumbar arthrodesis is performed using OssiMend Bioactive Moldable as the bone grafting material. The primary endpoints are radiographic evidence of fusion and the absence of serious adverse events attributable to OssiMend Bioactive Moldable. The secondary objective is to evaluate the clinical outcomes over a period of 1 year (2 years, if possible).
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Subject must be 18 years of age or older at the time of consent and must have a documented diagnosis of degenerative disc disease (DDD) that has failed to respond to nonoperative treatment for at least 6 months. DDD is defined by back and/or radicular pain with degeneration of the disc as confirmed by medical history, physical examination, and radiographic studies that may include CT, MRI, plain X-ray film, discography, myelography, etc. with one or more of the following findings: * Instability as defined by \>3mm translation or \>5 degrees angulation * Osteophyte f…
Interventions
- DeviceOssiMend™ Bioactive Moldable
Lumbar Spine fusion with OssiMend™ Bioactive Moldable
Locations (4)
- San Diego NeurosurgeryEncinitas, California
- Hartford HospitalHartford, Connecticut
- University Orthopaedic Associates, Division of OrthoNJSomerset, New Jersey
- McKenzie-willamette Medical CenterEugene, Oregon